跳转至内容
Merck
CN
  • Trends and predictors of smoking cessation after percutaneous coronary intervention (from Olmsted County, Minnesota, 1999 to 2010).

Trends and predictors of smoking cessation after percutaneous coronary intervention (from Olmsted County, Minnesota, 1999 to 2010).

The American journal of cardiology (2014-12-30)
Ondrej Sochor, Ryan J Lennon, Juan Pablo Rodriguez-Escudero, John F Bresnahan, Ivana Croghan, Virend K Somers, Francisco Lopez-Jimenez, Quinn Pack, Randal J Thomas
摘要

Smoke-free ordinance implementation and advances in smoking cessation (SC) treatment have occurred in the past decade; however, little is known about their impact on SC in patients with coronary artery disease. We conducted a retrospective cohort study of 2,306 consecutive patients from Olmsted County, Minnesota, who underwent their first percutaneous coronary intervention (PCI) from 1999 to 2009, and assessed the trends and predictors of SC after PCI. Smoking status was ascertained by structured telephone survey 6 and 12 months after PCI (ending in 2010). The prevalence of smoking in patients who underwent PCI increased nonsignificantly from 20% in 1999 to 2001 to 24% in 2007 to 2009 (p = 0.14), whereas SC at 6 months after PCI decreased nonsignificantly from 50% (1999 to 2001) to 49% (2007 to 2009), p = 0.82. The 12-month quit rate did not change significantly (48% in 1999 to 2001 vs 56% in 2007 to 2009, p = 0.38), even during the time periods after the enactment of smoke-free policies. The strongest predictor of SC at 6 months after PCI was participation in cardiac rehabilitation (odds ratio [OR] 3.17, 95% confidence interval [CI] 2.05 to 4.91, p <0.001), older age (OR 1.42 per decade, 95% CI 1.16 to 1.73, p <0.001), and concurrent myocardial infarction at the time of PCI (OR 1.77, 95% CI 1.18 to 2.65, p = 0.006). One-year mortality was lower in the group of smokers compared with never smokers (3% vs 7%, p <0.001). In conclusion, SC rates have not improved after PCI over the past decade in our cohort, despite the presence of smoke-free ordinances and improved treatment strategies. Improvements in delivery of systematic services aimed at promoting SC (such as cardiac rehabilitation) should be part of future efforts to improve SC rates after PCI.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
胆固醇, Sigma Grade, ≥99%
Sigma-Aldrich
胆固醇, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
SyntheChol ® NS0 补充, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Sigma-Aldrich
胆固醇, from sheep wool, ≥92.5% (GC), powder
Supelco
胆固醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
胆固醇 溶液, certified reference material, 10 mg/mL in chloroform
SAFC
胆固醇, from sheep wool, Controlled origin, meets USP/NF testing specifications
Sigma-Aldrich
胆固醇, tested according to Ph. Eur.